Literature DB >> 18564126

Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States.

Edward V Loftus1, David J Delgado, Howard S Friedman, William J Sandborn.   

Abstract

PURPOSE: We sought to describe the types of colectomy, follow-up surgical/diagnostic procedures, and complications occurring within 180 days of colectomy in a population of privately insured individuals with ulcerative colitis (UC).
METHODS: This was a retrospective analysis of claims data of privately insured patients (MarketScan) for the years 2001-2004. We identified a cohort of patients with UC who underwent colectomy. Colectomies were classified into four categories based on the surgery occurring on the first colectomy date: (a) total proctocolectomy (TPC) with ileal pouch-anal anastomosis (IPAA), (b) subtotal colectomy (SC) with ileostomy and Hartmann pouch or ileorectal anastomosis, (c) TPC with ileostomy, and (d) partial colectomy (PC). Follow-up surgical/diagnostic procedures and complications were compared across colectomy categories.
RESULTS: A total of 25,586 UC patients were identified, of whom 215 patients had a colectomy and at least 180 days of pre- and postcolectomy follow-up. The colectomy distribution was: TPC-IPAA (52%), SC-ileostomy (22%), TPC-ileostomy (14%), and PC (13%). Within 180 days postcolectomy, 54% of patients had a second colectomy-related surgery (including unplanned surgeries in 15.3%), and 27% had a follow-up diagnostic procedure. Postcolectomy complications included abscesses (11.6% in the first 30 days postcolectomy, 16.3% in the day 31-180 postcolectomy period), fistulas (4.2% early, 6.0% late), and sepsis/pneumonia/bacteremia (7.9% early, 9.3% late).
CONCLUSION: Postcolectomy surgical procedures and complications occur frequently after colectomy in privately insured patients with UC.

Entities:  

Mesh:

Year:  2008        PMID: 18564126     DOI: 10.1111/j.1572-0241.2008.01867.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  16 in total

1.  Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom.

Authors:  Michele R Wilson; Annika Bergman; Helene Chevrou-Severac; Ross Selby; Michael Smyth; Matthew C Kerrigan
Journal:  Eur J Health Econ       Date:  2017-03-08

2.  The impact of Hispanic ethnicity and race on post-surgical complications in patients with inflammatory bowel disease.

Authors:  Andres J Yarur; Maria T Abreu; Mark S Salem; Amar R Deshpande; Daniel A Sussman
Journal:  Dig Dis Sci       Date:  2013-03-13       Impact factor: 3.199

3.  Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Munira Essat; Paul Tappenden; Shijie Ren; Alice Bessey; Rachel Archer; Ruth Wong; Alan Lobo; Sami Hoque
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

4.  Topiramate use does not reduce flares of inflammatory bowel disease.

Authors:  Seth D Crockett; Robin Schectman; Til Stürmer; Michael D Kappelman
Journal:  Dig Dis Sci       Date:  2014-02-07       Impact factor: 3.199

Review 5.  Current treatment of ulcerative colitis.

Authors:  Johannes Meier; Andreas Sturm
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 6.  Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults.

Authors:  Gerda C Leitner; Harald Vogelsang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

7.  Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study.

Authors:  Seth D Crockett; Richard A Hansen; Til Stürmer; Robin Schectman; Jane Darter; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2011-08-08       Impact factor: 5.325

8.  Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.

Authors:  S Singh; H C Heien; L R Sangaralingham; S R Schilz; M D Kappelman; N D Shah; E V Loftus
Journal:  Aliment Pharmacol Ther       Date:  2016-03-15       Impact factor: 8.171

9.  Drivers of cost after surgical and medical therapy for chronic ulcerative colitis: a nested case-cohort study in Olmsted County, Minnesota.

Authors:  Stefan D Holubar; Rajesh Pendlimari; Edward V Loftus; James P Moriarty; Dirk Larson; Megan O'Byrne; John H Pemberton; Robert R Cima
Journal:  Dis Colon Rectum       Date:  2012-12       Impact factor: 4.585

Review 10.  Poorly responsive ulcerative colitis in the hospital.

Authors:  Millie D Long; Scott E Plevy
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-21       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.